Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options

Table 1 Selected clinical trials on targeted agents for advanced/metastatic thyroid carcinomas

Trial	Phase	Setting	Patients	Targeted agent	DCR
Cooney et al[38]	II	Advanced pretreated disease	18 with ATC	CA4P alone	33%
Cohen et al[46]	II	Advanced pretreated disease	60 (2 with ATC)	Axitinib alone	71%
Ha et al[53]	II	Advanced pretreated disease	11 with ATC	Imatinib alone	75%
Nagaiah et al[54]	II	Advanced pretreated disease	16 with ATC	Sorafenib alone	40%

ATC: Anaplastic thyroid carcinoma; CA4P: Combretastatin A4; DCR: Disease control rate (complete responses + partial responses + stable disease).

Table 2 Ongoing clinical trials of targeted therapies for thyroid cancer

Clinicaltrials.gov identifier	Investigational drug	Phase study	Eligible population	Planned enrolment	Primary end point	Status
NCT00389441	Axitinib	Phase II, single arm	Radioiodine-refractory thyroid cancer, regardless of histology	52	Overall response rate	Active, not recruiting
NCT00510640	Sunitinib	Phase II, single arm	Thyroid cancer, regardless of histology	66	Overall response rate	Recruiting
NCT00095836	Gefitinib	Phase II, single arm	Thyroid cancer, regardless of histology	38	Overall response rate	Active, not recruiting
NCT01164176	Everolimus	Phase II, single arm	Thyroid cancer, regardless of histology	32	Overall response rate	Recruiting
NCT01118065	Everolimus	Phase II, single arm	Thyroid cancer, regardless of histology	42	Overall response rate	Recruiting
NCT00654238	Sorafenib	Phase II, single arm	Thyroid cancer, regardless of histology	55	Overall response rate	Recruiting
NCT00625846	Pazopanib	Phase II, single arm	Thyroid cancer, regardless of histology	188	Overall response rate	Recruiting
NCT01236547	Pazopanib	Phase II, two arms	Anaplastic thyroid cancer	99	Overall response rate	Recruiting
		Paclitaxel neoadjuvant, concomitant and adjuvant to radiotherapy with or without pazopanib
NCT00126568	Sorafenib		Anaplastic thyroid cancer	36	Overall response rate	Recruiting
NCT00603941	CS7017	Phase I/ II	Anaplastic thyroid cancer	54	Maximum tolerated dose/Overall response rate	Active, not recruiting
NCT00115739	Imatinib	Phase II	Anaplastic thyroid cancer	29	Overall response rate	Active, not recruiting